Literature DB >> 28068223

Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.

Xiaobo Wang1, Ze Zheng2, Jorge Matias Caviglia3, Kathleen E Corey4, Tina M Herfel5, Bishuang Cai2, Ricard Masia6, Raymond T Chung4, Jay H Lefkowitch7, Robert F Schwabe3, Ira Tabas8.   

Abstract

Nonalcoholic steatohepatitis (NASH) is a leading cause of liver disease worldwide. However, the molecular basis of how benign steatosis progresses to NASH is incompletely understood, which has limited the identification of therapeutic targets. Here we show that the transcription regulator TAZ (WWTR1) is markedly higher in hepatocytes in human and murine NASH liver than in normal or steatotic liver. Most importantly, silencing of hepatocyte TAZ in murine models of NASH prevented or reversed hepatic inflammation, hepatocyte death, and fibrosis, but not steatosis. Moreover, hepatocyte-targeted expression of TAZ in a model of steatosis promoted NASH features, including fibrosis. In vitro and in vivo mechanistic studies revealed that a key mechanism linking hepatocyte TAZ to NASH fibrosis is TAZ/TEA domain (TEAD)-mediated induction of Indian hedgehog (Ihh), a secretory factor that activates fibrogenic genes in hepatic stellate cells. In summary, TAZ represents a previously unrecognized factor that contributes to the critical process of steatosis-to-NASH progression.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28068223      PMCID: PMC5226184          DOI: 10.1016/j.cmet.2016.09.016

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  62 in total

1.  A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.

Authors:  Zobair M Younossi; Sandra Page; Nila Rafiq; Aybike Birerdinc; Maria Stepanova; Noreen Hossain; Arian Afendy; Zahra Younoszai; Zachary Goodman; Ancha Baranova
Journal:  Obes Surg       Date:  2011-04       Impact factor: 4.129

2.  PP1 cooperates with ASPP2 to dephosphorylate and activate TAZ.

Authors:  Chen-Ying Liu; Xianbo Lv; Tingting Li; Yanping Xu; Xin Zhou; Shimin Zhao; Yue Xiong; Qun-Ying Lei; Kun-Liang Guan
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

Review 3.  An ARC light on lipid metabolism.

Authors:  Robert B Rawson
Journal:  Cell Metab       Date:  2006-09       Impact factor: 27.287

4.  Conditional deletion of Indian hedgehog from collagen type 2alpha1-expressing cells results in abnormal endochondral bone formation.

Authors:  Mohammed S Razzaque; Desi W Soegiarto; Da Chang; Fanxin Long; Beate Lanske
Journal:  J Pathol       Date:  2005-12       Impact factor: 7.996

5.  Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity.

Authors:  Lale Ozcan; Catherine C L Wong; Gang Li; Tao Xu; Utpal Pajvani; Sung Kyu Robin Park; Anetta Wronska; Bi-Xing Chen; Andrew R Marks; Akiyoshi Fukamizu; Johannes Backs; Harold A Singer; John R Yates; Domenico Accili; Ira Tabas
Journal:  Cell Metab       Date:  2012-04-12       Impact factor: 27.287

6.  Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice.

Authors:  Savitha Subramanian; Leela Goodspeed; Shari Wang; Jinkyu Kim; Lixia Zeng; George N Ioannou; W Geoffrey Haigh; Matthew M Yeh; Kris V Kowdley; Kevin D O'Brien; Subramaniam Pennathur; Alan Chait
Journal:  J Lipid Res       Date:  2011-06-20       Impact factor: 5.922

Review 7.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

Review 8.  The melanocortin receptors: lessons from knockout models.

Authors:  A A Butler; R D Cone
Journal:  Neuropeptides       Date:  2002 Apr-Jun       Impact factor: 3.286

9.  Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.

Authors:  Wing-Kin Syn; Steve S Choi; Evaggelia Liaskou; Gamze F Karaca; Kolade M Agboola; Ye Htun Oo; Zhiyong Mi; Thiago A Pereira; Marzena Zdanowicz; Padmini Malladi; Yuping Chen; Cynthia Moylan; Youngmi Jung; Syamal D Bhattacharya; Vanessa Teaberry; Alessia Omenetti; Manal F Abdelmalek; Cynthia D Guy; David H Adams; Paul C Kuo; Gregory A Michelotti; Peter F Whitington; Anna Mae Diehl
Journal:  Hepatology       Date:  2010-10-21       Impact factor: 17.425

Review 10.  Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge.

Authors:  Bram Piersma; Ruud A Bank; Miriam Boersema
Journal:  Front Med (Lausanne)       Date:  2015-09-03
View more
  115 in total

1.  MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.

Authors:  Yong He; Seonghwan Hwang; Yan Cai; Seung-Jin Kim; Mingjiang Xu; Dingcheng Yang; Adrien Guillot; Dechun Feng; Wonhyo Seo; Xin Hou; Bin Gao
Journal:  Hepatology       Date:  2019-06-05       Impact factor: 17.425

2.  Mouse Models of Liver Fibrosis.

Authors:  Aashreya Ravichandra; Robert F Schwabe
Journal:  Methods Mol Biol       Date:  2021

3.  MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway.

Authors:  Tianpeng Zhang; Junjie Hu; Xiaomei Wang; Xiaoling Zhao; Zhuoyu Li; Junqi Niu; Clifford J Steer; Guohua Zheng; Guisheng Song
Journal:  J Hepatol       Date:  2018-09-13       Impact factor: 25.083

4.  Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer.

Authors:  Sun-Hye Jeong; Han-Byul Kim; Min-Chul Kim; Ji-Min Lee; Jae Ho Lee; Jeong-Hwan Kim; Jin-Woo Kim; Woong-Yang Park; Seon-Young Kim; Jae Bum Kim; Haeryoung Kim; Jin-Man Kim; Hueng-Sik Choi; Dae-Sik Lim
Journal:  J Clin Invest       Date:  2018-02-05       Impact factor: 14.808

5.  The Hippo Pathway and YAP Signaling: Emerging Concepts in Regulation, Signaling, and Experimental Targeting Strategies With Implications for Hepatobiliary Malignancies.

Authors:  Nathan Werneburg; Gregory J Gores; Rory L Smoot
Journal:  Gene Expr       Date:  2019-06-28

Review 6.  The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease.

Authors:  Yue Zhao; Tian-Yu Wu; Meng-Fei Zhao; Chao-Jun Li
Journal:  J Biol Chem       Date:  2020-03-05       Impact factor: 5.157

7.  Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol.

Authors:  Stefano Spolitu; Haruka Okamoto; Wen Dai; John A Zadroga; Erika S Wittchen; Jesper Gromada; Lale Ozcan
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

8.  Low-density lipoprotein receptor-related protein-1 dysfunction synergizes with dietary cholesterol to accelerate steatohepatitis progression.

Authors:  Allyson N Hamlin; Sivaprakasam Chinnarasu; Yinyuan Ding; Xunde Xian; Joachim Herz; Anja Jaeschke; David Y Hui
Journal:  J Biol Chem       Date:  2018-05-11       Impact factor: 5.157

Review 9.  The hedgehog pathway in nonalcoholic fatty liver disease.

Authors:  Mariana Verdelho Machado; Anna Mae Diehl
Journal:  Crit Rev Biochem Mol Biol       Date:  2018-03-20       Impact factor: 8.250

10.  Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.

Authors:  KyeongJin Kim; Dongryeol Ryu; Paola Dongiovanni; Lale Ozcan; Shruti Nayak; Beatrix Ueberheide; Luca Valenti; Johan Auwerx; Utpal B Pajvani
Journal:  Gastroenterology       Date:  2017-08-30       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.